

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 April 2011 (14.04.2011)

PCT

(10) International Publication Number
WO 2011/044008 A1

- (51) **International Patent Classification:**
A61K 9/70 (2006.01) *A61K 47/38* (2006.01)
- (21) **International Application Number:**
PCT/US2010/051257
- (22) **International Filing Date:**
4 October 2010 (04.10.2010)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/249,788 8 October 2009 (08.10.2009) US
- (71) **Applicant (for all designated States except US):**
SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC. [US/US]; 3030 Jackson Avenue, Memphis, Tennessee 38151 (US).
- (72) **Inventors; and**
- (75) **Inventors/Applicants (for US only):** **DEVER, Gerald R.** [US/US]; 3030 Jackson Avenue, Memphis, Tennessee 38151 (US). **SU, Eric Chen-Nan** [US/US]; 3030 Jackson Avenue, Memphis, Tennessee 38151 (US). **ROGERS, William Scott** [US/US]; 3030 Jackson Avenue, Memphis, Tennessee 38151 (US).
- (74) **Agent:** **SCHERING CORPORATION**; Schering Corporation, Matthew J. Golden, 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))



WO 2011/044008 A1

(54) **Title:** LOW ETHER COMPOSITION AND DELIVERY APPARATUS

(57) **Abstract:** A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.

Low Ether Composition and Delivery Apparatus

This application claims priority to US Provisional Application Serial No. 61/249,788, filed October 8, 2009. The contents of that application are incorporated in
5 their entirety into this specification by reference.

Background

Periodic medication dispensing delivery systems have recently been developed to provide for unit dosage delivery of cosmetic and medicinal products. These systems are designed to be easy to manipulate so as to dispense and apply the
10 medicinal product. These systems include devices such as the pen-type dispensers described in US Patent No. 7,309,185 and US Published Application No. 2007/0020038, which are said to allow for storage of a cosmetic or medicinal product in a device that also contains an integrated apparatus for application of the product. These devices are said to be useful for a variety of cosmetic or medicinal products
15 including dentifrices, such as tooth gel, tooth paste, mouthwash, mouth rinse, tooth whitener, cosmetics such as mascara and eyeliner, hair care products and/or skin treatment compositions.

Certain topical medicinal/cosmetic compositions that comprise volatile solvents that might make use of such delivery systems have heretofore not been made
20 available in such systems. In particular, these devices could be useful for topical liquid cosmetic or medicinal compositions, except for the fact that the compositions contain large amounts volatile solvents necessary as delivery vehicles for active ingredients and additional agents, such as film forming agents. For example, US Patent No. 5,433,950 describe certain liquid and gel formulations for treating skin lesions, which
25 formulations contain a flexible collodion vehicle comprising nitrocellulose film forming agent in volatile solvents, primarily diethyl ether. Such compositions can contain active ingredients, such as keratolytic agents, for treatment of skin lesions such as warts, calluses and corns, or other skin disorders such as acne, or psoriasis. Because of the presence of volatile solvents in these formulations any substantial escape of solvent

from such a periodic dosing device before first use or between uses will result in the treatment compositions having higher active ingredient concentrations than currently allowed by regulatory agencies.

Thus, there is a need for volatile containing cosmetic or medicinal compositions that maintains acceptable active ingredient concentrations in the compositions when packaged in a periodic dispensing delivery system. Further, there is a need for a film forming medical composition that provides sufficient film forming capabilities yet maintains acceptable active ingredient concentrations in the compositions when contained in a periodic dispensing delivery system. Such compositions will better resist the loss of excessive amounts of volatile solvents which will result in increasing the concentration of the active agents beyond regulatory allowances for such drug products and still form useful treatment films upon application. These and other objectives are provided by the invention more fully described and claimed herein.

All patent and non-patent references cited herein are hereby incorporated in their entirety into this specification by reference thereto. Identification or discussion of any reference in this section or any part of this specification shall not be construed as an admission that such reference is available as prior art to the present application.

Summary of the Invention

This invention provides a gel composition for topical application comprising salicylic acid or salt thereof in a concentration up to about 17% (w/w), a film forming agent, and one or more volatile ingredients, wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w)

The invention further provides a gel composition for topical application comprising salicylic acid in a concentration up to approximately 17% (w/w), a collodion product in an amount between about 5 to about 20% (w/w) and one or more volatile ingredients, wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w).

The invention also provides a gel composition for topical application comprising salicylic acid in a concentration up to approximately 17% (w/w) and nitrocellulose in an

amount between 0.2 and about 1.0% (w/w).

The invention further provides a gel composition for application to skin comprising a keratolytic agent and comprising a collodion product in an amount between about 5% and 20% (w/w) and one or more volatile ingredients, wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w), which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin.

The invention also provides a gel composition for application to skin comprising a keratolytic agent and comprising a nitrocellulose in an amount between about 0.2% and 1.0% (w/w) and one or more volatile ingredients, wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w), which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin.

The invention also provides a method of treating a skin ailment on a subject comprising applying to the skin a composition of the invention, wherein the composition forms a film on contact with skin adequate to form a protective barrier for salicylic acid for a period of time necessary to provide treatment to the lesion.

The invention further provides a dispenser for administering a composition for treating a skin ailment on a subject wherein the dispenser comprises a gel composition of the invention in a reservoir in communication with a dispensing means and means for retarding evaporation of volatile materials in the composition prior to application to a subject.

Brief Description of the Figures

Figure 1 - graph depicting mean percent weight loss of pens filled with control and invention gel formulations held at room temperature (RT) and elevated temperature (40C) for 13 weeks.

Figure 2 – photomicrograph at 20X magnification showing film formed by liquid control formulation.

Figure 3 – photo micrograph at 30X magnification showing film formed by gel control formulation.

Figure 4 – photomicrograph at 20X magnification showing film formed by invention gel formulation.

5 **Detailed Description**

As described herein, the present invention provides enhancements to compositions containing active ingredients and volatile solvents and to delivery devices that store and deliver such compositions. In certain embodiments the compositions also contain film forming agents. The compositions of the invention
10 provide for reduced loss of volatile ingredients when the composition is stored in and applied from such delivery device. In certain embodiments, the device comprises a pen-type delivery system designed to conveniently apply formulations to skin to treat a variety of skin conditions.

Formulations

15 In one embodiment the invention provides a liquid composition for topical application comprising a cosmetically or medicinally active agent and wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w). In certain embodiments, the ether content is between about 6% to about 10% (w/w). In certain embodiments, the ether content is between about 6% to about 7%
20 (w/w). In certain embodiments the ether can comprise an ether useful in cosmetic or medicinal compositions, in particular diethyl ether. In certain embodiments the compositions may contain additional volatile alcohol ingredient can comprise an alcohol useful in cosmetic or medicinal compositions such as methanol, ethanol and propanol, and mixtures thereof.

25 In certain embodiments, the formulations of the invention are useful to treat skin lesions such as warts, corns and calluses. In other embodiments, the formulations are used to treat other ailments such as acne, psoriasis, dry skin, onychomycosis, ingrown toenails and the like. When formulated as wart treatment product or corn and callus treatment products, certain embodiments of the invention will contain salicylic acid as

the active agent. Where the composition is intended to treat disorders or diseases of the nail (i.e. onychomycosis), other active ingredients can be added, such as antifungal agents including clotrimazole, butenafine, terbinafine, miconazole, for example. As used herein, the term "salicylic acid" includes the acid and any salts or esters thereof that are acceptable for use in a topically applied composition. Suitable salts include the sodium, potassium, calcium, lithium or magnesium salts thereof. Suitable esters include the C₁ to C₄ esters thereof, such as methyl salicylate. Other esters include salsalate (salicylsalicylic acid), the salicylate ester of salicylic acid. Most preferably the acid form is employed as the active ingredient. Salicylic acid is also known as 2-hydroxybenzoic acid. Optionally, other ingredients can be employed in the topical preparation to assist penetration of salicylic acid into the nail and/or skin. Such agents can include nail softeners and avulsers, such as urea, sulfhydryl agents and sulfur-based reducing agents such as sodium sulfide, nail penetration enhancers, and occluding agents and/or hydrophillic fillers to promote hydration of the nail and/or skin.

USFDA Monograph regulations dictate limits of active ingredient concentrations in wart treatment products and corn/callus treatment products to allow for marketing of the product without further agency review. Under such regulations, compositions sold specifying concentrations salicylic acid concentrations are specifically regulated. Thus, in certain embodiments the compositions may contain salicylic acid in an amount up to about 17% (w/w). In certain embodiments the compositions may contain salicylic acid in an amount between about 5% and about 17%. However, the teaching of the subject invention contemplates higher content of salicylic acid in such formulations as one of ordinary skill in the art can prepare despite whether such formulations would fall within the regulations of certain medicinal or cosmetic products.

In other embodiments, the invention further comprises a gel composition for topical application comprising salicylic acid and which contains a collodion product in an amount between about 5 to about 20% (w/w). As used herein the term collodion product includes both collodion and flexible collodion. Collodion products are USP defined formulations comprising nitrocellulose, diethyl ether and ethyl alcohol. Nitrocellulose acts as a film forming agent that protects the active ingredient, here salicylic acid, from evaporation for a period of time sufficient for the active ingredient to

effect treatment. Flexible collodion differs from collodion by the addition of camphor and castor oil as plasticizing agents. In certain embodiments the composition will contain a collodion product in an amount between about 5% to about 10% (w/w). Thus, in certain
5 embodiments, the invention provides a liquid composition for application to a skin lesion comprising salicylic acid and comprising nitrocellulose in an between about 0.2% and 1.0% (w/w) wherein the composition forms a film on contact with skin that is adequate to form a protective barrier for salicylic acid for a period of time necessary to provide treatment to the lesion. In certain embodiments the composition may comprise nitrocellulose in an amount between about 0.25% and about 0.50% (w/w).

10 In certain embodiments, the invention provides a salicylic acid formulation that reduces the amount of the most volatile solvents historically used in these type formulations, such as ethyl ether, which has a boiling point = 34.5 C, while still maintaining a viable gel formulation that can be applied drop-wise from the periodic unit dosage dispenser on to the surface of a subject in need thereof. Application of
15 salicylic acid formulation from such a device will form a salicylic acid-delivering film on the skin. In certain embodiments, the invention comprises a formulation that contains low amounts of low boiling point solvents, for example, those with boiling points lower than 40C, such as ethyl ether, and comprises higher amounts of higher-boiling point solvents, for example those with boiling points above about 70C that still dissolve the
20 film-forming polymers and produce good films when applied to the skin. Examples of such higher boiling solvents include for example, ethyl acetate (boiling point p =77 C) and isobutyl acetate (boiling point = 118 C).

In certain embodiments, the compositions of the invention may further comprise additional thickening/viscosifying agents. For example, cellulosic polymers such as
25 hydroxypropyl cellulose, including Klucel® HF (Hercules Inc. Aqualon Division Hopewell, VA USA), can be added in an amount up to about 2.6%. In certain embodiments, the formulations of the invention further comprise reduced amounts of ethyl lactate, which is a plasticizer for both nitrocellulose and hydroxypropyl cellulose, so as to be present in an amount to improve the strength/flexibility of the applied,
30 dried films produced by the formulations.

In certain embodiments, the formulations of the invention may contain additional nitrocellulose in an amount to improve the strength/flexibility of the applied, dried films. For example, the formulations may contain nitrocellulose from a pyroxylin solution in an appropriate higher boiling point solvent such as ethyl acetate or other alkyl acetates, as mentioned above. Such pyroxylin solutions are commercially available (CAS 9004-70-0) (Alfa Chem, Kings Point, NY USA) and have been used in cosmetic applications such as nail polish and in furniture lacquers. In certain embodiments, the invention may comprise nitrocellulose-compatible polymers to improve the film-forming characteristics, for example Gantrez polymeric materials such as Gantrez ES-425, Gantrez ES 335-I, and Gantrez ES-225 produced by ISP International Specialty Products (Wayne, NJ, USA). These Gantrez polymers are alkyl esters of polymethyl vinyl ether/maleic acid (PVM/MA), including butyl, isopropyl, and ethyl esters of PVM/MA. Those of ordinary skill in the art will recognize that the appropriate PVM/MA polymers will display compatibility with the other polymeric film formers/viscosifying agents in the proposed formulations in order to form good quality, strong, flexible films upon application.

In certain embodiments, the compositions of the invention may comprise a local anesthetic in compounds used for traditional wart therapy, the present invention alleviates the localized discomfort and irritation often associated with the application of keratolytics to the skin. Local anesthetics include, but are not limited to, esters of benzoic acid such as benzocaine, procaine, tetracaine, and chlorprocaine, and amides such as bupivacaine, dibucaine, lidocaine, mepivacaine, prilocaine, and etidocaine. The amount of local anesthetic present will be that which is effective in achieving localized anesthesia in the area to which the composition is applied, generally from about 0.5% to about 15% or more and preferably from 1% to 10% by weight of composition. For lidocaine, for example, the effective range is from about 0.5% to about 4%. With benzocaine, the effective range is from about 5% to about 25%.

Methods of Treatment

The invention further provides methods of treating various skin ailments with the low ether content compositions of the invention. Thus, in certain embodiments the invention provides a method of treating an ailment on a subject comprising applying to the subject a composition comprising a keratolytic agent and comprising nitrocellulose in an amount between about 0.2 and 1.0% (w/w) to the affected area, wherein the composition forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the affected area. As demonstrated below, gel compositions formulated with the low ether content of the present invention provide surprisingly superior films to prior compositions. It is thus believed the compositions will provide for advances in treatments of disorders that are amenable to treatment with such compositions due to the benefits from enhanced exposure to the active agents from the improved films. In certain embodiments the keratolytic agent may be salicylic acid, ascorbic acid, calcium pantothenate, glacial acetic acid, lactic acid, podophyllum resin, and zinc chloride or combinations thereof. In certain embodiments, salicylic acid may be present in an amount up to about 17%. In certain embodiments salicylic acid may be present in an amount between about 5% (w/w) and 17% (w/w). In certain embodiments, the ailment may comprise a skin lesion such as warts, corns and calluses. In other embodiments, the ailment may comprise acne, psoriasis, dry skin, onychomycosis, or ingrown toenails.

Keratolytic agents are used topically in the treatment of hyperkeratosis and act by softening and destroying the stratum corneum layer of the skin, thereby enhancing desquamation at the site of application. Thus in one aspect the present invention is useful in the treatment of hyperkeratosis using a film-forming fluid composition of the invention comprising a keratolytic agent such as salicylic acid, flexible collodion and a topically acceptable polymer in an amount sufficient to increase the resilience of the film formed will exhibit the improved compliance and improved therapeutic efficacy.

The present invention also includes the method of treating warts which comprises applying to the wart a composition comprising a therapeutically effective amount of at least one composition of the invention. In certain embodiments the method comprises applying a composition of the invention comprising salicylic acid or

a salt thereof. Generally, the composition can be applied to the wart daily or for intermittent intervals, such as for two to three times per week. The duration of treatment may vary greatly, depending on the size of the wart.

5 The present invention further includes a method of treating onychomycosis which comprises applying to a nail a composition comprising a therapeutically effective amount of at least one composition of the invention. Generally, the preparation can be applied to the nail daily or for intermittent intervals, such as for two to three times per week. The duration of treatment can vary greatly, depending upon the degree of severity of the infection, the part of the body where the nail is being treated, the age of
10 the person, the thickness of the nail, the rate of nail growth and the like. Generally, the toenails of a younger person can be expected to receive treatments up to 6 months, whereas the toenails of an older person can be expected to receive treatment up to about one year. These periods reflect the time required for toenails to completely grow out of the toe. Treatment of fingernails can be expected to be faster, since fingernail
15 growth is approximately twice as fast as toenail growth. Effectiveness of the treatment can be evaluated by the subsidence or disappearance of symptoms. Less severe cases where only part of the distal portion of the nail is infected can be expected to require less time for treatment.

20 **Device**

The invention further provides a dispenser for administering a composition for treating a skin disorder as described herein wherein the dispenser comprises a liquid composition of the invention in a reservoir in communication with a dispensing means and means for retarding evaporation of volatile materials in the composition prior to
25 application to a subject. In certain embodiments of the invention, the dispenser is in the form of a pen-like device.

In certain embodiments, the dispenser comprises additional means for retarding evaporation of volatile ingredients of the compositions, such as a pouch that is fabricated from barrier films and that is sealed after the dispenser is placed inside. In
30 additional embodiments, the means for retarding evaporation of volatile materials is placement of a sealing mechanism between the reservoir and the dispensing means.

In certain embodiments the invention provides a means to apply salicylic acid containing formulations to a subject in need thereof by applying the formulation from a device comprising a reservoir holding the salicylic acid formulation, a dispensing tip for communicating the formulation from the reservoir to the surface of a subject, such as skin or nails or hair surface, and pressure mechanism for forcing the formulation through the dispensing tip. The pressure mechanism can be a plunger operated mechanically by the user or similar mechanism that forces the formulation through an opening in a dispensing tip. The invention also provides for a dispensing device designed to retard evolution of the volatile solvent ingredients out of the pen dispenser system. In certain embodiments the dispensing device comprises a pen-type dispenser with a barrel shaped reservoir containing the salicylic acid, a dispensing tip which retains the formulation in the reservoir until pressure on the reservoir causes the formulation to move through a barrier in the dispensing tip and forms a droplet to be applied to the surface of a subject in need thereof. Pressure can be applied, for example, by use of a plunger that is activated by the subject. The device can optionally contain a cap for enclosing the dispenser tip when not in use. Improvements provided by the current invention include design elements of the pen itself including style and materials of construction of the sealant means. In certain prior art devices the sealant means is an "O" ring located at the plunger end of the pen dispenser opposite the dispensing tip end of the device. In certain embodiments, the invention comprises equipping the device with a plurality of rubber "O" ring-type or equivalent sealant means, made from suitable, solvent-resistant materials, at the dispenser tip end, to seal off any evolution of volatile formulation ingredients from a filled device. In addition, the device of the invention may comprise one or more solvent barrier film adhesive tapes, for example such as 9792R Aluminum Tape available from 3M (St. Paul, MN, USA) to seal the joints in the pens, such as between a cap covering the pen dispenser tip and the formulation-filled pen barrel. In certain embodiments, the device of the invention further may comprise encasing the device in secondary packaging, either in combination with, or independent of, the above mentioned formulation modifications, sealants, taping, for example by placing the filled dispenser device in a pouch made from heat-sealable, laminate packaging film, such as a PET/aluminum

foil/adhesive material such as those available from Hueck Foils, (e.g., TPMSF005SB) (Wall, NJ, USA).

Experimental

5 Table 1 shows experimental gel formulations containing 17% w/w salicylic acid that were prepared and compared with two known salicylic acid formulations to determine their ability to withstand volatile evaporation in pen-like dispenser devices. The gel control formulation contains lower collodion amounts, and thus lower ether content, than the liquid control and added alcohol. The experimental gel formulations
10 were designed with lower amounts of collodion than the gel control formulation to further lower the volatile ingredient and decrease evaporation of solvent, yet still produce a viable film upon application to skin. All amounts in the table are listed by percent by weight of formulation. Weight amounts are listed for the flexible collodion components (pyroxylin (nitrocellulose), castor oil, camphor, ethanol, and ethyl ether)
15 based on their weight percent in flexible collodion.

Table 1

Ingredient	Ex 1	Ex 2	Ex 3	Ex 4	Gel Control	Liquid Control
Alcohol SDA-40B	51.60	51.60	51.60	51.60	51.60	0.00
Ethyl Lactate	10.00	15.00	20.00	25.00	5.00	15.00
Indopol L-50	0.10	0.10	0.10	0.10	0.10	0.10
Salicylic Acid USP	17.00	17.00	17.00	17.00	17.00	17.00

Ingredient	Ex 1	Ex 2	Ex 3	Ex 4	Gel Control	Liquid Control
Collodion, flexible USP	20.00	15.00	10.00	5.00	25.00	64.9
(pyroxylin)	0.98	0.74	0.49	0.25	1.23	3.19
(castor oil)	0.60	0.45	0.30	0.15	0.75	1.95
(camphor)	0.40	0.30	0.20	0.10	0.50	1.30
(ethanol)	4.84	3.63	2.43	1.22	6.05	15.8
(diethyl ether)	13.2	9.87	6.58	3.29	16.5	42.7
Klucel HF	1.30	1.30	1.30	1.30	1.30	0.00
Total	100	100	100	100	100	100

All formulations were prepared in jars using a compressed-air operated mixing motor, a double-blade mixing shaft. Para films are used to cover the opening of the jar during the mixing operation. Alcohol, ethyl lactate and Indopol L-50 were first charged into the jar and mixed for 10 minutes. Then salicylic acid was added into the mixture and mixed for 30 minutes. Next, flexible collodion was added into the mixture and mixed for 10 minutes. Then Klucel HF powder was slowly added into the mixture while mixing over a period of about 3 to 5 minutes and the final mixture is further mixed for 30 minutes to complete the compounding.

Example gel formulations 3 and 4 were chosen for further analysis in comparison to the gel control formulation to determine the effects of formulation on volatile evaporation over time at room temperature and at 40 C when stored in pen-like dispenser devices. Formulations were loaded into 60cc syringes which were used to fill the gel solutions into the pen barrels. The pen barrels were sealed with plastic inserts, covered with silicone nose tips and snap fit with caps. The pen samples were

aged at room temperature and at 40°C for 13 weeks. Figure 1 shows the results of the testing showing that the formulations of the invention provide substantial improvement in the reduction of loss of volatile ingredients over time at both room temperature and elevated temperature conditions.

5 Example gel formulation 3 was further subjected to an in vitro film forming test in comparison to the liquid control formulation. Figure 2 is a photomicrograph of a sample of two drops of the control liquid formulation deposited on a glass microscope slide with an eye dropper, and then dried for several minutes until completely dry. The digital microscopy image was done at magnification 20X. The marker on the
10 micrograph shows that the dried film dot on the glass slide is about 7.5 mm in diameter. Figure 3 is a photomicrograph of two drops of control gel formulation deposited on a glass microscope slide with an eye dropper, and then dried for several minutes until completely dry. The image was created using the same microscope at 30X magnification. The marker on the micrograph shows that the dried film dot is about
15 4 mm in diameter. Figure 4 is a photomicrograph of two drops of example gel formulation 3 deposited on a glass microscope slide with an eye dropper, and then dried for several minutes until completely dry. The image was created using the same microscope at 20X magnification. The marker on the micrograph shows that the dried film dot is about 8.1 mm in diameter.

20 Comparison of Figure 2 (liquid control), Figure 3 (gel control) and Figure 4 (example formulation 3) show the unexpected benefit in film formation demonstrated by the example formulation of the invention. The dried film dot from the liquid control and gel formulas dry first around the outside circumference of the drops, resulting in a much thicker, "mountain-range-like" film in that area. Because of that, there is
25 substantially less material deposited on the slide in the regions interior to the mountain-range and the films are not uniform in thickness across their area. The control films also demonstrate an aggregated structure of many small micron-sized sub-particles and sub-particle agglomerates. In contrast, the dried film from example gel formulation 3 dries uniformly across its whole surface, not from the edges, and
30 although some larger aggregates of smaller particles are visible, as a whole it is denser and more uniform across its entire area.

What is claimed is:

1. A gel composition for topical application comprising salicylic acid or salt thereof in a concentration up to about 17% (w/w), a film forming agent, and one or more volatile ingredients, wherein the composition comprises ether in an amount of
5 between about 3% (w/w) and about 14% (w/w).
2. The gel composition of claim 1, wherein the salicylic acid or salt thereof is present in an amount between about 5% and about 17% (w/w).
10
3. The gel composition of claim 1, wherein the ether is present in an amount between about 6% to about 10% (w/w).
4. The gel composition of claim 1, wherein the ether is present in an amount
15 between about 6% to about 7% (w/w).
5. A gel composition for topical application comprising salicylic acid in a concentration up to approximately 17% (w/w), a collodion product in an amount between about 5 to about 20% (w/w).
20
6. The gel composition of claim 5 which comprises a collodion product in an amount between about 5 to about 10% (w/w).
7. A gel composition for topical application comprising salicylic acid in a
25 concentration up to approximately 17% (w/w) and nitrocellulose in an amount between 0.2 and about 1.0% (w/w).
8. The gel composition of claim 7 which comprises nitrocellulose in an amount between about 0.25% to about 0.5% (w/w).
30
9. A wart treatment product comprising the composition of claim 1.

10. A corn/callus treatment product comprising the composition of claim 1.
- 5 11. A gel composition for application to skin comprising a keratolytic agent and comprising a collodion product in an amount between about 5% and 20% (w/w) and one or more volatile ingredients, wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w), which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin.
- 10 12. The gel composition of claim 11 which comprises a collodion product in an amount between about 5 to about 10% (w/w).
13. The gel composition of claim 11, wherein the ether is present in an amount between about 6% to about 10% (w/w).
- 15 14. The gel composition of claim 11, wherein the ether is present in an amount between about 6% to about 7% (w/w).
15. The gel composition of claim 11, wherein the keratolytic agent is chosen from
20 salicylic acid, ascorbic acid, calcium pantothenate, glacial acetic acid, lactic acid, podophyllum resin, and zinc chloride or combinations thereof.
16. The gel composition of claim 15, wherein the keratolytic agent is salicylic acid.
- 25 17. The gel composition of claim 16, wherein salicylic acid is present in an amount up to about 17% (w/w).
18. The gel composition of claim 16, wherein salicylic acid may be present in an amount between about 5% (w/w) and 17% (w/w).
- 30

19. A gel composition for application to skin comprising a keratolytic agent and comprising a nitrocellulose in an amount between about 0.2% and 1.0% (w/w), and wherein the composition comprises ether in an amount of between about 3% (w/w) and about 14% (w/w), which forms a film on contact with skin adequate to
5 form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin.

20. The gel composition of claim 19, wherein the nitrocellulose is present in an amount between about 0.25 to about 0.50% (w/w).

10 21. The gel composition of claim 19, wherein the ether is present in an amount between about 6% to about 10% (w/w).

15 22. The gel composition of claim 19, wherein the ether is present in an amount between about 6% to about 7% (w/w).

20 23. The gel composition of claim 19, wherein the keratolytic agent is chosen from salicylic acid, ascorbic acid, calcium pantothenate, glacial acetic acid, lactic acid, podophyllum resin, and zinc chloride or combinations thereof.

24. The gel composition of claim 23, wherein the keratolytic agent is salicylic acid.

25 25. The gel composition of claim 24, wherein salicylic acid is present in an amount up to about 17% (w/w).

26. The gel composition of claim 24, wherein salicylic acid may be present in an amount between about 5% (w/w) and 17% (w/w).

30 27. The gel composition of claims 11, and 19, further comprising an anesthetic.

28. A method of treating a skin ailment on a subject comprising applying to the skin a composition of claim 1, wherein the composition forms a film on contact with skin adequate to form a protective barrier for salicylic acid for a period of time necessary to provide treatment to the lesion.

5

29. A dispenser for administering a composition for treating a skin ailment on a subject wherein the dispenser comprises a gel composition of claim 1 in a reservoir in communication with a dispensing means and means for retarding evaporation of volatile materials in the composition prior to application to a subject.

10

30. The dispenser of claim 29 in the form of a pen-like device.

31. The dispenser of claim 29, wherein the means for retarding evaporation of volatile materials is a pouch that is sealed after the dispenser is placed inside.

15


32. The dispenser of claim 29, wherein the pouch comprises barrier film.


33. The dispenser of claim 29, wherein the means for retarding evaporation of volatile materials is placement of a sealing mechanism between the reservoir and the dispensing means.


20

34. A method for improving topical delivery of salicylic acid to a subject in need thereof, the method comprising topically administering to the subject the composition of claim 1.

25









INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/51257

A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - A61K 9/70; A61K 47/38 (2010.01)
USPC - 424/486; 424/400; 424/407; 424/487

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): A61K 9/70; A61K 47/38 (2010.01)
USPC: 424/486; 424/400; 424/407; 424/487

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

IPC(8): A61K 9/70; A61K 47/38 (2010.01)
USPC: 424/486; 424/400; 424/407; 424/487 (keyword delimited)

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB,USPT,USOC,EPAB,JPAB); Google Scholar
Search terms used: (dispenser OR applicator) pen gel (cosmetic OR skin OR dermatology) (evaporation OR evaporating OR evaporate) (bag OR pouch) barrier salicylic acid collodion nitrocellulose wart corn callus anesthetic ether volatile

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2006/0110415 A1 (GUPTA) 25 May 2006 (25.05.2006), entire document, especially: Abstract; para [0039], [0067]-[0070], [0082], [0107]	1-4, 34
Y		5-26, 28-33
Y	US 5,525,358 A (POPP) 11 June 1996 (11.06.1996), col. 1, ln 34-40; col. 3, ln 22-27; col. 4, ln 26-33; col. 6, ln 5-10	5, 6, 9-18
Y	US 2007/0048355 A1 (PERLMAN) 01 March 2007 (01.03.2007), para [0002], [0057]-[0060]	7, 8, 19-26, 28
Y	US 2007/0209133 A1 (LINZELL) 13 September 2007 (13.09.2007), Abstract; para [0017], [0071], [0081]	29-33
Y	US 4,149,814 A (MANWARING) 17 April 1979 (17.04.1979), col. 4, ln 40-49; Fig. 1	33

Further documents are listed in the continuation of Box C.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier application or patent but published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search 13 November 2010 (13.11.2010)	Date of mailing of the international search report 02 DEC 2010
--	--

Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-3201	Authorized officer: Lee W. Young PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774
---	--

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/51257

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

- 2. Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

- 3. Claims Nos.: 27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
- 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

- 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - No protest accompanied the payment of additional search fees.